



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	Anti-HIV-1 gp120 Monoclonal (F105)
Catalog Number:	857
Lot Number:	098326
Release Category:	C
Provided:	100 µg at 1.5 mg/ml.
Description:	Protein G-purified from tissue culture supernatant, quantitated by ELISA, dialyzed against PBS and sterile filtered. Immunoreactivity with HIV-1 infected cells is confirmed by flow cytometry and purity is assessed by SDS-PAGE analysis. The antibody is stable at this concentration. If a less concentrated stock is needed, dilute the material no further than 1 mg/mL, and use it within three months.
Host Site:	Human EBV-transformed B cell x HMMA2.11TG/O myeloma.
Titer:	Use 2 µg of antibody per million cells in flow cytometry and immunofluorescence assays, and 1-10 µg/ml for neutralization assays. Other applications will vary with the requirements of the experimental system.
Special Characteristics:	F105 reacts with a discontinuous, or conformational, gp120 epitope. Binds to gp120 on the surface of IIIB, SF2, MN, RF, and CC-infected cells. Neutralizes SF2, IIIB, and MN infection at concentrations ranging from 140 ng/ml to 10 µg/ml.
Recommended Storage:	Keep at 4°C for short term storage and -80°C for long term storage. Avoid freeze-thaw cycles as reagent degradation may result.
Contributor:	Dr. Marshall Posner and Dr. Lisa Cavacini.
Isotype:	IgG ₁ , kappa.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References:

Posner MR, et al. *J Acquired Immune Defic Syndr* **6**:7-14, 1993.
Cavacini LA, et al. *J Acquired Immune Defic Syndr* **6**:353-358, 1993.
Posner MR, et al. *Hybridoma* **6**:611-625, 1987.
Posner MR, et al. *J Immunol* **146**:4325-4332, 1991.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 gp120 Monoclonal (F105) from Dr. Marshall Posner and Dr. Lisa Cavacini." Also include the references cited above in any publications.

US Patent No. 5215913. Requests from commercial organizations should be directed to Jodi Hecht, Technology Ventures Office, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215. Email: jehecht@bidmc.harvard.edu.

Last Updated

May 18, 2015

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.